EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access

Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis

Andreas Kerschbaumer, Josef S Smolen, Ricardo J O Ferreira, Heidi Bertheussen, Xenofon Baraliakos, Daniel Aletaha, Dennis G McGonagle, Désirée van der Heijde, Iain B McInnes, Bente Appel Esbensen, Kevin L Winthrop, Wolf-Henning Boehncke und 2 weitere

Annals of the Rheumatic Diseases · 2024-06 · 83 (6) · 760-774

DOI: 10.1136/ard-2024-225534 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Annals of the Rheumatic Diseases, 2024-06. Verfasst von Andreas Kerschbaumer und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria andreas.kerschbaumer@meduniwien.ac.at. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Antirheumatic Agents. Die Arbeit wurde bisher 82-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: The European Alliance of Associations for Rheumatology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: To obtain an overview of recent evidence on efficacy and safety of pharmacological treatments in psoriatic arthritis (PsA). METHODS: This systematic literature research (SLR) investigated the efficacy and safety of conventional synthetic (cs), biological (b) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs) in patients with PsA. A systematic database search using Medline, EMBASE, Cochrane CENTRAL was conducted to identify relevant articles published since the previous update in 2019 until 28 December 2022. Efficacy was assessed in trials while for safety observational data were also considered. Adverse events of special interest were infections (including herpes zoster, influenza and tuberculosis), malignancies, major adverse cardiovascular events, venous thromboembolisms, liver disease, laboratory changes and psychiatric adverse events. No meta-analyses were performed. RESULTS: For efficacy, of 3946 articles screened, 38 articles (30 trials) were analysed. The compounds investigated included csDMARDs (leflunomide, methotrexate), bDMARDs inhibiting IL17 (bimekizumab, brodalumab, ixekizumab, izokibep, secukinumab,), IL-23 (guselkumab, risankizumab, tildrakizumab), IL-12/23 (ustekinumab) as well as TNF (adalimumab, certolizumab-pegol, etanercept, infliximab, golimumab) and Janus Kinase inhibitors (JAKi) (brepocitinib, deucravacitinib, tofacitinib, upadacitinib). The compounds investigated were efficacious in improving signs and symptoms of PsA, improving physical functioning and quality of life. For safety, 2055 abstracts were screened, and 24 articles analysed: 15 observational studies and 9 long-term follow-ups of trials, assessing glucocorticoids, TNFi, IL-17i, JAKi, IL-12/23i and PDE4i (apremilast). Safety indicators were generally coherent with the previous SLR in 2019. CONCLUSION: The results of this SLR informed the task force responsible for the 2023 update of the European Alliance of Associations for Rheumatology recommendations for pharmacological management of PsA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, PsoriaticAntirheumatic AgentsHumansTreatment OutcomePractice Guidelines as TopicBiological Products

Stichwörter der Autor:innen

Biological TherapyDMARDs (synthetic)Psoriatic ArthritisTherapeutics

Substanzen

Antirheumatic AgentsBiological Products

Autor:innen und Institutionen

  • Department of Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria andreas.kerschbaumer@meduniwien.ac.at.
  • Department of Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria.
  • Nursing Research, Innovation and Development Centre of Lisbon (CIDNUR), Higher School of Nursing of Lisbon, Lisboa, Portugal.
  • Rheumatology Department, Centro Hospitalar e Universitario de Coimbra EPE, Coimbra, Portugal.
  • EULAR Patient Research Partner, Oslo, Norway.
  • Rheumazentrum Ruhrgebiet, Ruhr University Bochum, Herne, Germany.

Förderung

  • The European Alliance of Associations for Rheumatology

Zitieren

APA

Kerschbaumer, A., Smolen, J. S., Ferreira, R. J. O., Bertheussen, H., Baraliakos, X., Aletaha, D., McGonagle, D. G., van der Heijde, D., McInnes, I. B., Esbensen, B. A., Winthrop, K. L., Boehncke, W. H., Schoones, J. W., & Gossec, L. (2024). Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. Annals of the Rheumatic Diseases, 83(6), 760-774. https://doi.org/10.1136/ard-2024-225534

Vancouver

Kerschbaumer A, Smolen JS, Ferreira RJO, Bertheussen H, Baraliakos X, Aletaha D, et al. Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. Annals of the Rheumatic Diseases. 2024;83(6):760-774. doi:10.1136/ard-2024-225534

BibTeX
@article{Kerschbaumer2024,
  author = {Kerschbaumer, Andreas and Smolen, Josef S and Ferreira, Ricardo J O and Bertheussen, Heidi and Baraliakos, Xenofon and Aletaha, Daniel and McGonagle, Dennis G and van der Heijde, Désirée and McInnes, Iain B and Esbensen, Bente Appel and Winthrop, Kevin L and Boehncke, Wolf-Henning and Schoones, Jan W and Gossec, Laure},
  title = {Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis},
  journal = {Annals of the Rheumatic Diseases},
  year = {2024},
  volume = {83},
  number = {6},
  pages = {760--774},
  doi = {10.1136/ard-2024-225534}
}
Kostenlos starten →